How Much Do GLP-1 Medications Cost with Insurance? (2026 Guide)
How Much Do GLP-1 Medications Cost with Insurance? (2026 Guide)
The Short Answer
- With insurance + copay card: $0–$25/mo. Novo Nordisk and Eli Lilly both offer free copay cards for commercially insured patients.[1][2]
- List price is $936–$1,349/mo — but nobody should pay that. Manufacturer direct programs start at $199/mo.[3][4]
- Yes, Medicare covers this starting July 2026. The Bridge Program covers Wegovy and Zepbound at $50/mo.[5]
- Most major insurers cover at least one GLP-1 with prior authorization. 43% of large employers now cover for weight loss, up from 28% in 2024.[7]
- If denied, appeal it — 82% of appeals are overturned. The Obesity Action Coalition has free sample appeal letters.[9][10]
You see the pharmacy price tag — $1,349 for Wegovy, $1,086 for Zepbound — and your stomach drops. Then you find a Reddit thread where someone paid $0, and wonder what you are doing wrong. This is the most common pattern in GLP-1 communities: price shock followed by confusion about what the real cost is supposed to be.
The gap between list price and what you actually pay is enormous — often over $1,000. List prices are negotiating figures between manufacturers and insurance companies. They show up on benefit summaries and pharmacy screens, but they have almost nothing to do with what leaves your bank account. This guide maps every cost path: with insurance, without it, on Medicare, and self-pay direct. Twelve sources, five questions answered, one table you can screenshot.
What You'll Actually Pay
Every GLP-1 medication has a list price and a real price. The difference between them depends on your coverage scenario. The table below shows actual patient costs across four situations and the three most-prescribed medications.[1]
| Coverage scenario | Wegovy | Zepbound | Ozempic |
|---|---|---|---|
| With insurance + copay card | $0[2] | $25[11] | $0–$25[3] |
| With insurance, no copay card | $25–$150 | $25–$150 | $25–$100 |
| Medicare (Jul–Dec 2026) | $50/mo[5] | $50/mo[5] | Covered for T2D only[6] |
| Self-pay (manufacturer direct) | $199 intro / $349 ongoing[3][4] | $299–$449 via LillyDirect[11] | $199 intro[4] |
List prices for reference: Wegovy $1,349/mo,[2] Ozempic $936/mo,[12] Zepbound $1,086/mo.[11] These numbers appear on benefit summaries and pharmacy screens, but they are not what patients pay. They exist as the starting point in negotiations between drug makers and pharmacy benefit managers.
The copay card is the single most important step for commercially insured patients. Novo Nordisk's card brings Wegovy to $0 per fill for eligible patients with commercial insurance.[2] Eli Lilly's savings program brings Zepbound to $25.[11] Both are free to activate and apply automatically at the pharmacy — but you have to sign up before your first fill. The cards do not work with government insurance (Medicare, Medicaid, TRICARE).
For patients without insurance, manufacturer direct programs now offer prices far below list. Novo Nordisk launched a $199/mo introductory offer for both Wegovy and Ozempic, running through June 2026.[4] After the intro period, ongoing self-pay through NovoCare is $349/mo.[3] Eli Lilly sells Zepbound single-dose vials through LillyDirect starting at $299/mo, with higher doses at $449/mo.[11]
what Ozempic costs in the US versus the UK
Wegovy is $1,349 in the US versus $82 in the UK. American list prices are 10–16x higher than peer nations — which is why copay cards, manufacturer programs, and the new Medicare pricing matter so much.[12]
How to Get Your Insurance to Say Yes
Every commercial plan requires prior authorization for GLP-1 weight loss prescriptions. This is not a rejection — it is a documentation step. Physicians submit an average of 39 PAs per week; your doctor's office has done this before.[9] The 43% of large employers covering GLP-1s for weight management all require it.[7]
The criteria across major insurers follow a common pattern: documented BMI, at least one weight-related comorbidity, and evidence of prior weight loss attempts. Here is the four-step process that maximizes your approval odds.
BMI ≥30 (or ≥27 with a comorbidity like hypertension, type 2 diabetes, or sleep apnea) must be coded as an active diagnosis — not just mentioned in visit notes. ICD-10 codes must be current: E66.01 (morbid obesity), I10 (hypertension), E11 (T2D), G47.33 (sleep apnea). Prior weight loss attempts (diet, exercise, or other medications) also need documentation.
The PA form requires diagnosis codes, measured BMI (self-reported numbers are typically rejected), comorbidity documentation, and history of prior interventions. Some plans require 3–6 months of documented weight management effort. Standard insurer turnaround is 3–5 business days.
Formularies are drug-specific, not class-wide. CVS Caremark moved Wegovy to preferred status in July 2025 but removed Zepbound.[8] If one GLP-1 is excluded from your plan, the competitor may be covered at a lower tier.
If You Get Denied
A denial is not the end — statistically, it is barely the middle. The AMA's 2024 prior authorization survey found that 82% of appealed PA denials are eventually overturned.[9] Most denials are administrative: missing documentation, a wrong diagnosis code, or an incomplete form. They are not clinical judgments that your doctor was wrong to prescribe the medication.
The problem is that most patients give up after the first "no." They assume the decision is final. It is not. Here are three steps, in order of leverage.
Request the letter with the specific reason code — never rely on a phone summary. Each code points to a targeted fix: "not medically necessary" needs stronger clinical documentation; "step therapy required" means a prior drug trial or a step-therapy exception; "missing information" means the PA was incomplete and can be resubmitted with the gap filled.
Ask your doctor to call the insurer's reviewing physician directly. This is the highest-leverage step in the entire appeal process — the reviewing physician can overturn the denial on that single call. It is underused because most patients do not know to ask for it. Tell your doctor's office: "Please request a peer-to-peer review for my denied GLP-1 prior authorization."[9]
The Obesity Action Coalition provides free sample appeal letters and a step-by-step guide for GLP-1 denials.[10] Submit the appeal with updated documentation addressing the exact denial reason: new labs, updated BMI, specialist letters, or evidence of failed prior interventions. If the internal appeal fails, you have the legal right to an external review by an independent third party under the ACA.
What's Changing
"Medicare doesn't cover weight loss drugs."
This was true through early 2026. A Medicare bridge program launches July 2026 covering Wegovy and Zepbound at $50/month. Full Part D GLP-1 coverage begins January 2027 under the CMS BALANCE model. The statute is changing — the old rule no longer applies.[5][6]
Three policy changes are converging to reshape GLP-1 access in 2026 and 2027. For the 12.5 million Medicare beneficiaries who qualify, this is the most significant coverage expansion since Part D launched.
Medicaid expands. The CMS BALANCE model opens Medicaid GLP-1 coverage nationally at $50/mo for qualifying beneficiaries.[6]
Medicare bridge launches. Wegovy and Zepbound covered at $50/month for Medicare beneficiaries meeting obesity criteria. This is a temporary program bridging to full coverage.[5]
Full Part D coverage. GLP-1s for weight management become standard Part D benefits under the BALANCE model.[6]
For commercially insured patients, the landscape is also shifting. Novo Nordisk's $199/mo introductory offer for Wegovy and Ozempic runs through June 2026.[4] Eli Lilly's LillyDirect sells Zepbound single-dose vials starting at $299/mo.[11] Both represent manufacturer end-runs around the insurance system — direct-to-patient pricing that did not exist a year ago. The direction is clear: every major path to GLP-1 access is getting cheaper, and the biggest change — Medicare coverage — is months away, not years.
Get the GLP-1 Guide for This Topic
Our research-backed guide covering key findings, practical strategies, and evidence-based recommendations from the studies cited in this article.
Free PDF · No spam · Unsubscribe anytime
Sources
- GoodRx. "GLP-1 Drugs Cost and Savings." goodrx.com. 2026. Source →
- Novo Nordisk. "Save on Wegovy." wegovy.com. 2026. Source →
- Novo Nordisk. "NovoCare Wegovy Patient Support." novocare.com. 2026. Source →
- Novo Nordisk. "Introductory Self-Pay Offer for Wegovy and Ozempic for $199/mo." PR Newswire. 2025. Source →
- CMS. "Medicare GLP-1 Bridge Program." cms.gov. 2026. Source →
- CMS. "BALANCE Model." cms.gov. 2026. Source →
- Kaiser Family Foundation. "2025 Employer Health Benefits Survey." kff.org. 2025. Source →
- CVS Caremark. "GLP-1 Formulary Management." business.caremark.com. 2025. Source →
- American Medical Association. "2024 Prior Authorization Survey." ama-assn.org. 2024. Source →
- Obesity Action Coalition. "Appealing a Denial — Access to Care Resources." obesityaction.org. 2026. Source →
- Eli Lilly. "Zepbound Savings." zepbound.lilly.com. 2026. Source →
- Peterson-KFF Health System Tracker. "Prices of Drugs for Weight Loss in the US and Peer Nations." healthsystemtracker.org. 2025. Source →
Get the GLP-1 Guide for This Topic
Key findings, practical strategies, and evidence-based recommendations — backed by the clinical studies cited above. Free PDF, straight to your inbox.
Free PDF · No spam · Unsubscribe anytime
Pricing & coverage disclaimer
Drug prices, insurance coverage, and patient assistance programs change frequently. The information in this article was verified as of April 2026 using official manufacturer, government, and insurer sources. Your actual cost depends on your specific insurance plan, pharmacy, location, and eligibility. Always verify current pricing with your pharmacy and insurer before making decisions.
Sources: All pricing data sourced from manufacturer websites (Novo Nordisk, Eli Lilly), government agencies (CMS, FDA, CBO), insurer formularies (UHC, Cigna, Aetna, Anthem), pharmacy pricing platforms (GoodRx, Costco), and policy research organizations (KFF, ICER). Community context from r/Ozempic, r/Mounjaro, and r/Semaglutide. No affiliate links. No sponsored content.
